Login / Signup

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.

Julia EckardtChristopher SchroederPeter MartusSorin Armeanu-EbingerOlga KelemenAxel GschwindIrina BonzheimThomas EigentlerTeresa AmaralStephan OssowskiOlaf RießLukas FlatzClaus GarbeAndrea Forschner
Published in: Journal of cancer research and clinical oncology (2022)
BRAF mutation status and TMB were independent predictive factors for RFS. Patients with BRAF V600E/K mutation and TMB high had the best outcome. A classification based on BRAF mutation status and TMB is proposed to predict RFS in melanoma patients with adjuvant anti-PD-1 therapy.
Keyphrases
  • metastatic colorectal cancer
  • early stage
  • wild type
  • deep learning
  • stem cells
  • mesenchymal stem cells
  • skin cancer
  • bone marrow
  • smoking cessation